Results 41 to 50 of about 34,922 (258)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease

eNeurologicalSci, 2018
We conducted a phase I study investigating the efficacy, safety, and tolerability of ONO-2160, a newly developed levodopa pro-drug, and carbidopa compared with levodopa and carbidopa to stabilize levodopa plasma concentration fluctuations in Japanese ...
Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Rina Ando, Yoshifumi Kagamiishi, Koji Yano, Shigeto Saito, Atsushi Takeda   +7 more
doaj   +1 more source

Intranasal Delivery of Gallium–Quercetin Nanoparticles for Multi‐Target Ferroptosis Inhibition in Parkinson's Disease

Advanced Science, EarlyView.
Leveraging the chemical similarity between Ga3+ and Fe3+ as well as the antioxidant properties of quercetin, gallium–quercetin nanoparticles (GQNPs) were prepared to integrate iron homeostasis regulation, oxidative stress suppression, and mitochondrial protection for multi‐target ferroptosis inhibition in Parkinson's Disease.
Keyang Xu, Dandan Kou, Xiao Xiao, Bingbing Bai, Caide Liu, Mengyao Wu, Yadan Shi, Mengdan Xu, Xiaoyi Cao, Haodi Qi, Shuhua Wu, Jianfeng Zeng, Mingyuan Gao   +12 more
wiley   +1 more source

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Parkinson's Disease, 2022
Background. Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson’s disease and as an adjunct therapy to levodopa in Parkinson’s disease with motor fluctuations. Objectives.
Osamu Kano, Hiroshi Tsuda, Ayako Hayashi, Masaki Arai   +3 more
doaj   +1 more source

Speech Biomarkers for Quantifying Effects of Subthalamic Deep Brain Stimulation in Parkinson's Disease

Annals of Neurology, EarlyView.
Objective Dysarthria is one of the most common and disabling side effects of subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). Stimulation often exacerbates speech dysfunction beyond the effects of PD progression, likely because of current spread to structures surrounding the STN.
Petr Krýže, Mário Sousa, Vojtěch Illner, Adriana Jorge, Matilde Castelli, Ines Debove, Andreia D. Magalhães, Julia Waskönig, Lenard Lachenmayer, Joan Philipp Michelis, Gerd Tinkhauser, Deborah Amstutz, Marie Elise Maradan‐Gachet, Katrin Petermann, Claudio Pollo, Tobias Nef, Paul Krack, Jan Rusz   +17 more
wiley   +1 more source

NMDAR‐antibody encephalitis: Seizure semiology and EEG findings

Epileptic Disorders, EarlyView.
Abstract Background N‐methyl‐D‐aspartate receptor antibody encephalitis (NMDAR‐Ab‐E) is an autoantibody‐mediated disorder, characterized by acute development of neuropsychiatric symptoms, seizures, movement disorders, and autonomic instability. Objectives To describe acute seizure semiology and electroencephalogram (EEG) findings in patients with a ...
Maria Emilia C. Andraus, Bernard Liem, Sidra Aurangzeb, Mkael Symmonds, Adam E. Handel, Sarosh R. Irani, Arjune Sen   +6 more
wiley   +1 more source

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics

Frontiers in Pharmacology
Levodopa is the gold standard treatment for Parkinson’s disease. However, a high unmet medical need exists for longer-lasting oral levodopa formulations to achieve sustained motor improvement with reduced risk of the effect wearing off.
Akane Hayashi, Atsushi Hosomi, Shinsaku Kihara, Masato Nishi, Saori Torisawa, Yoshiumi Ouchi, Hidenori Takada, Junichi Enokizono   +7 more
doaj   +1 more source

Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes

Neurobiology of Disease, 2008
Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR)
C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso   +5 more
doaj   +1 more source

Effects of on Levodopa Pharmacokinetics

Journal of Parkinson’s Disease, 2021
Background: Infection with Helicobacter pylori seems overrepresented in Parkinson’s disease. Clinical observations suggest a suboptimal treatment effect of levodopa in Helicobacter positive patients. Objective: Describe and explain the connection between
Dag Nyholm, Per M. Hellström
doaj   +1 more source

Implantable electrochemical sensors for continuous blood monitoring

FlexMat, EarlyView.
Implantable electrochemical sensors enable direct, in situ, and continuous blood monitoring, shifting diagnosis from population‐based averages to dynamic, individualized analysis. This review systematically examines the influence of the unique blood properties on sensor design.
Kuangyi Zou, Yuanzhen Wang, Haidong Wang, Ye Zhang   +3 more
wiley   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source